|Bid||7.79 x 21500|
|Ask||7.90 x 27000|
|Day's range||7.42 - 7.91|
|52-week range||7.23 - 10.50|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||10.11|
TEL AVIV, Israel, July 01, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, NJ.
TEL AVIV, Israel, June 29, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
There are two things that Teva Pharmaceutical Industries (NYSE: TEVA) and Amazon (NASDAQ: AMZN) have in common. While the index fell by 38% during that time, the healthcare company climbed 10% in value, and the tech giant's 8% decline was modest by comparison. Teva provides patients with generic medications that are much cheaper than brand-name drugs.